Vineet Sankhla/X
Sep 8, 2026, 09:42
Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
Vineet Sankhla, Interventional Cardiologist Health New Zealand – Te Whatu Ora, shared a post on X:
“More bleeding with Prasu/Tica plus DOACs in AF patients undergoing PCI.
Clopidogrel may be safer choice in triple anti platelet therapy.
EPIDAURUS: Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and ACS undergoing PCI.”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 09:23Mehdi Mirsaeidi: Platelets and Thromboinflammation in COPD
-
Sep 8, 2026, 09:03Michel Cabrera Ortega: LAAC vs OAC – Which Risk Are We Trading?
-
Sep 8, 2026, 08:58Zehraan Ibni Akbar: Peripheral Blood Smear – A Window into Hematological Diagnosis
-
Sep 8, 2026, 08:50Dirk Sibbing: Potent P2Y12 Inhibition in Patients With Atrial Fibrillation and Acute Coronary Syndrome
-
Sep 8, 2026, 08:39ASH-a-Palooza – Exploring What’s Next in Hematology
-
Sep 8, 2026, 08:23Khaled Musallam: A Masterclass on Thalassemia Care in the MENA Region
-
Sep 8, 2026, 08:23Atoosa Salimi: The Role of Platelet-Derived Serotonin in Severe COVID-19
-
Sep 8, 2026, 07:59Mohammedsefa Arusi Dari: Exploring the Link Between Iron Deficiency Anemia and Sleep Apnea
-
Sep 8, 2026, 07:50Isabelle Ducellier: Exploring the Science Behind Improved Iron Uptake